/HSTO
HSTO Stock - Histogen Inc.
Healthcare|BiotechnologyNASDAQ
$0.02+0.00%
62
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.50
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.75
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.02
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for HSTO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.02 – $0.02
TARGET (TP)$0.02
STOP LOSS$0.02
RISK/REWARD1:NaN
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.12
52W High$0.02
52W Low$0.02
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | $3.77M | $919,000 | $2.06M | $11.45M | $33.59M |
| Gross Profit | $3.77M | $699,000 | $1.09M | $9.09M | $33.59M |
| Gross Margin | 100.0% | 76.1% | 53.0% | 79.4% | 100.0% |
| Operating Income | $-10,643,000 | $-15,457,000 | $-11,714,000 | $-12,006,000 | $-18,277,000 |
| Net Income | $-10,621,000 | $-14,950,000 | $-18,769,000 | $-11,385,000 | $-18,010,000 |
| Net Margin | -281.8% | -1626.8% | -911.6% | -99.4% | -53.6% |
| EPS | $-3.46 | $-7.51 | $-41.60 | $-5.02 | $-118.60 |
Company Overview
Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
HSTOBeat Rate
50%
Last 12 quarters
Avg Surprise
-339.8%
EPS vs Estimate
Beats / Misses
6/6
Last 12 quarters
Latest EPS
$-0.90
Q4 2023
EPS Surprise History
Q1 22
+36.4%
$-1.40vs$-2.20
Q2 22
+85.7%
$-0.20vs$-1.40
Q3 22
-10.7%
$-1.55vs$-1.40
Q4 22
+27.9%
$-1.01vs$-1.40
Q1 23
-29.8%
$-0.61vs$-0.47
Q2 23
+44.9%
$-0.81vs$-1.47
Q3 23
+45.6%
$-0.49vs$-0.90
Q4 23
-66.7%
$-0.90vs$-0.54
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2024 | Nov 18, 2024 | — | — | — | — |
Q3 2024 | Sep 26, 2024 | — | — | — | — |
Q2 2024 | Jun 19, 2024 | — | — | — | — |
Q1 2024 | Jan 4, 2024 | $-0.59 | — | — | — |
Q4 2023 | Nov 9, 2023 | $-0.54 | $-0.90 | -66.7% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-0.90 | $-0.49 | +45.6% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-1.47 | $-0.81 | +44.9% | ✓ BEAT |
Q1 2023 | Mar 9, 2023 | $-0.47 | $-0.61 | -29.8% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-1.40 | $-1.01 | +27.9% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-1.40 | $-1.55 | -10.7% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-1.40 | $-0.20 | +85.7% | ✓ BEAT |
Q1 2022 | Mar 10, 2022 | $-2.20 | $-1.40 | +36.4% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-2.20 | $-1.80 | +18.2% | ✓ BEAT |
Q3 2021 | Aug 11, 2021 | $-0.17 | $-2.00 | -1076.5% | ✗ MISS |
Q2 2021 | May 13, 2021 | $-0.15 | $-2.80 | -1766.7% | ✗ MISS |
Q1 2021 | Mar 11, 2021 | $-0.35 | $-5.20 | -1385.7% | ✗ MISS |
Q4 2020 | Nov 10, 2020 | — | $-5.40 | — | — |
Q3 2020 | Aug 13, 2020 | — | $-9.20 | — | — |
Q2 2020 | May 1, 2020 | — | $-3.12 | — | — |
Q1 2020 | Mar 11, 2020 | — | $-0.80 | — | — |
Latest News
Loading news...
Frequently Asked Questions about HSTO
What is HSTO's current stock price?
Histogen Inc. (HSTO) is currently trading at $0.02 per share. The stock has moved +0.00% today.
What is the analyst price target for HSTO?
No analyst price targets are currently available for this stock.
What sector is Histogen Inc. in?
Histogen Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is HSTO's market cap?
Histogen Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does HSTO pay dividends?
No, Histogen Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALRN
Aileron Therapeutics, Inc.
$2.11
Mkt Cap: $0.0B
ARTL
Artelo Biosciences, Inc.
$1.57
Mkt Cap: $0.0B
BLCM
Bellicum Pharmaceuticals, Inc.
$0.07
Mkt Cap: $0.0B
BTTX
Better Therapeutics, Inc.
$0.00
Mkt Cap: $0.0B
BXRX
Baudax Bio, Inc.
$0.02
0CING
Cingulate Inc.
$3.97
Mkt Cap: $0.0B
CRIS
Curis, Inc.
$1.07
Mkt Cap: $0.0B
CYTO
Altamira Therapeutics Ltd.
$0.30
Mkt Cap: $0.0B
DRUG
Bright Minds Biosciences Inc.
$84.00
Mkt Cap: $0.6B
ENTX
Entera Bio Ltd.
$1.77
Mkt Cap: $0.1B
Explore stocks similar to HSTO for comparison